Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

NCT04373265 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Adrenocortical Carcinoma

Interventions

DRUG: Relacorilant
DRUG: Pembrolizumab

Sponsor

Corcept Therapeutics